# US 2022/0033424 A1 · Fluorous metal chelates compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033424 A1
- Document ID: US20220033424A1
- Status: Published application
- Kind: A1
- Application number: 17/311,299
- Filed: 2019-12-09
- Published: 2022-02-03
- Earliest claimed: 2018-12-07
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Eric T. Ahrens; Stephen Adams; Chao Wang
- Web page: https://patentgrep.com/patent/US20220033424A1

## CPC

- A61K 31/295: Iron group metal compounds
- C07F 11/005: {compounds without a metal-carbon linkage}
- A61K 31/28: Compounds containing heavy metals
- A61K 49/106: {the complex-forming compound being cyclic, e.g. DOTA}
- A61K 49/1806: {Suspensions, emulsions, colloids, dispersions}
- C07C 251/24: having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
- C07F 15/025: {without a metal-carbon linkage}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

This disclosure provides compositions of SALTAME core containing compounds and associated methods for use in tracking cells by magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and related methods.

## Claims

### Claim 1

A composition comprising a compound comprising a salicylidene-tris(aminomethyl)ethane (SALTAME) core as described herein.

### Claim 2

A composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the group consisting of the following compounds:
wherein X is selected from the group consisting of 11C, 13N, 15O or 8F, and R1 to R12 are selected from the group consisting of: H, CH3, perfluorohexyl (PFH), perfluorooctyl (PFO), Me, CF3, O—(CF2)n—CF3, (CF2)n—CF3, and O—CF2—(OCF2CF2)n—O—Y, wherein n is 0 to 20, and Y is CF3, CF2—CF3 or CF2—CF2—CF3;
or
wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and Rf is (CF2)j CF3 or O—(CF2)j—CF3, and j is 0 to 20.

### Claim 3

A composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the group consisting of 5a POP (Fe SALTAME), 5a OOP (Fe SALTAME), 5a OOO (Fe SALTAME), 5c (Fe SALTAME), 5d (Fe SALTAME), 5e (Fe SALTAME), 5f (Fe SALTAME), 5g (Fe SALTAME), GA OOP, and GA POP.

### Claim 4

A composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the group consisting of the following compounds:

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1 to 4, wherein said compound comprising fluorine-19 (19F) comprises a perfluorinated compound.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein said compound comprising fluorine-19 (19F) comprises a metalated perfluorinated compound.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein said compound comprises a metal-binding moiety capable of binding metal ions.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said metal ions are selected from the group consisting of Co3+, VO2+, Cr3+, Mn2+, Mn3+, Mn4+, Fe2+, Fe3+, Ni2+, Cu2+, Ce3+, Pr3+, Nd3+, Sm3+, Eu3+, Gd3+, Tb3+, Dy3+, Ho3+, Er3+, Tm3+, Yb3+, 44Sc3+, 52Mn2+, 61Cu2+, 64Cu2+, Zn2+, 66Ga3+, 68Ga3+, 82Rb, 86Y3+, 89Zr4, 67Ga3+, 99mTc4+, 111In3+, and 177Lu3+.

### Claim 9 (depends on 7)

The composition of claim 7, wherein said metal ions are selected from the group consisting of Fe3+, Fe2+, Ga3+, Mn2+, Mn3+, Mn4+, Ni2+, Cu2+, Zn2+, Co3+, and Cr3+.

### Claim 10 (depends on 7)

The composition of claim 7, wherein said metal ions are selected from the group consisting of Mn4+, Fe3+, Co3+, and Ga3+.

### Claim 11 (depends on 7)

The composition of claim 7, wherein said metal ion is Fe3+.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1 to 11, wherein said compound has a solubility greater than 0.005 mol/L in perfluorocarbons selected from the group consisting of perfluorooctylbromide (PFOB), perfluoro-15-crown-5-ether (PFCE), and perfluoro (polyethylene glycol) (PFPE).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The composition of any one of claims 1 to 12, wherein said compound is stable in pH from 1 to 14.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1 to 13, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound changes the chemical shift of the SALTAME core in 19F nuclear magnetic resonance (19F-NMR).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The composition of any one of claims 1 to 14, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound reduces the T1 relaxivity of fluorine-19 (19F) in the SALTAME core.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The composition of any one of claims 1 to 15, wherein said compound is formulated as a nanoemulsion.

### Claim 17 (depends on 16)

The composition of claim 16, wherein said nanoemulsion further comprises a perfluorocarbon.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A composition comprising at least two or more said compounds of any one of claims 1 to 17.

### Claim 19

A non-invasive imaging method comprising:
a) administering to a subject a cellular labelling composition comprising a compound comprising fluorine-19 (19F), wherein said compound comprising a salicylidene-tris(aminomethyl)ethane (SALTAME) core comprising fluorine-19 (19F) associates with one or more cells, wherein said compound is a compound comprising a salicylidene-tris(aminomethyl)ethane (SALTAME) core as described herein; and
b) detecting said association using an imaging modality, wherein said association can include cellular binding and/or cellular uptake.

### Claim 20

A non-invasive imaging method comprising:
a) administering to a subject a cellular labelling composition comprising a compound comprising fluorine-19 (19F), wherein said compound comprising fluorine-19 (19F) associates with one or more cells and said compound is selected from the following compounds:
wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and R1 to R12 are selected from the group consisting of: H, CH3, perfluorohexyl (PFH), perfluorooctyl (PFO), Me, CF3, O—(CF2)n—CF3, (CF2)n—CF3, and O—CF2—(OCF2CF2)n—O—Y, wherein n is 0 to 20, and Y is CF3, CF2—CF3 or CF2—CF2—CF3;
or
wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and Rf is (CF2)j—CF3 or O—(CF2)j—CF3, wherein j is 0 to 20; and
b) detecting said association using an imaging modality, wherein said association can include cellular binding and/or cellular uptake.

### Claim 21

A non-invasive imaging method comprising:
a) administering to a subject a cellular labelling composition comprising a compound comprising fluorine-19 (19F), wherein said compound comprises a salicylidene-tris(aminomethyl)ethane (SALTAME) core comprising fluorine-19 (19F) associates with one or more cells, wherein said compound is a compound selected from the group consisting of 5a POP (Fe SALTAME), 5a OOP (Fe SALTAME), 5a OOO (Fe SALTAME), 5c (Fe SALTAME), 5d (Fe SALTAME), 5e (Fe SALTAME), 5f (Fe SALTAME), 5g (Fe SALTAME), GA OOP, and GA POP; and
b) detecting said association using an imaging modality, wherein said association can include cellular binding and/or cellular uptake.

### Claim 22

A non-invasive imaging method comprising:
a) administering to a subject a cellular labelling composition comprising a compound comprising fluorine-19 (19F), wherein said compound comprises a salicylidene-tris(aminomethyl)ethane (SALTAME) core comprising fluorine-19 (19F) associates with one or more cells, wherein said compound is one of the following compounds:
and
b) detecting said association using an imaging modality, wherein said association can include cellular binding and/or cellular uptake.

### Claim 23 (depends on 19, 20, 21, 22)

The method of any one of claims 19 to 22, wherein said imaging modality is selected from the group consisting of magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission coherent tomography (SPECT), ultrasonography (US), and computed tomography (CT).

### Claim 24 (depends on 19, 20, 21, 22, 23)

The method of any one of claims 19 to 23, wherein said compound comprising fluorine-19 (19F) comprises a perfluorinated compound.

### Claim 25 (depends on 19, 20, 21, 22, 23, 24)

The method of any one of claims 19 to 24, wherein said compound comprising fluorine-19 (19F) comprises a metalated perfluorinated compound.

### Claim 26 (depends on 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 19 to 25, wherein said compound comprises one or more metal-binding moieties capable of binding metal ions.

### Claim 27 (depends on 26)

The method of claim 26, wherein said metal ions are selected from the group consisting of Co3+, VO2+, Cr3+, Mn2+, Mn3+, Mn4+, Fe2+, Fe3+, Ni2+, Cu2+, Ce3+, Pr3+, Nd3+, Sm3+, Eu3+, Gd3+, Tb3+, Dy3+, Ho3+, Er3+, Tm3+, Yb3+, 44Sc3+, 52Mn2+, 61Cu2+, 64Cu2+, Zn2+, 66Ga3+, 68Ga3+, 82Rb, 86Y3+, 89Zr4, 67Ga3+, 99mTc4+, 111In3+, and 177Lu3+.

### Claim 28 (depends on 26)

The method of claim 26, wherein said metal ions are selected from the group consisting of Fe3+, Fe2+, Ga3+, Mn2+, Mn3+, Mn4+, Ni2+, Cu2+, Zn2+, Co3+, and Cr3+.

### Claim 29 (depends on 26)

The method of claim 26, wherein said metal ions are selected from the group consisting of Mn4+, Fe3+, Co3+, and Ga3+.

### Claim 30 (depends on 26)

The method of claim 26, wherein said metal ion is Fe3+.

### Claim 31 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 18 to 30, wherein said compound has a solubility greater than 0.005 mol/L in perfluorocarbons selected from the group consisting of perfluorooctylbromide (PFOB), perfluoro-15-crown-5-ether (PFCE), and perfluoro (polyethylene glycol) (PFPE).

### Claim 32 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 19 to 31, wherein said compound is stable in pH from 1 to 14.

### Claim 33 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 19 to 32, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound changes the chemical shift of the SALTAME core in 19F nuclear magnetic resonance (19F-NMR).

### Claim 34 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 19 to 33, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound reduces the T1 relaxivity of fluorine-19 (19F) in the SALTAME core.

### Claim 35 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 19 to 34, wherein said compound is formulated as a nanoemulsion.

### Claim 36 (depends on 35)

The method of claim 35, wherein said nanoemulsion further comprises a perfluorocarbon.

### Claim 37 (depends on 35)

The method of claim 35, wherein said nanoemulsion further comprises one or more targeting moieties, wherein the targeting moieties are selected from the group consisting of peptides, binding proteins, antibodies, antibody fragment thereof, and aptamers.

### Claim 38 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 19 to 37, wherein said composition allows tracking cells by MRI, wherein said method comprises detecting the cells associated with at least one component of the composition comprising fluorine-19 (19F).

### Claim 39 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 19 to 38, wherein said one or more cells are immune cells that accumulate at tissue sites as part of an inflammatory response.

### Claim 40 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 19 to 39, wherein said method is a diagnostic detection method.

### Claim 41 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 19 to 40, where said one or more cells are cells that are grafted into the body in order to treat a disease or condition.

### Claim 42 (depends on 41)

The method of claim 41, wherein said method is cytotherapy.

### Claim 43 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 19 to 42, wherein said one or more cells are endogenous cells in body of said subject.

### Claim 44 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 19 to 43, wherein said one or more cells are selected from the group consisting of T cells, B cells, macrophages, natural killer (NK) cells, dendritic cells (DCs), stem cells, progenitor cells, and cancer cells.

### Claim 45 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of claim any one of claims 19 to 44, wherein said one or more cells comprise engineered cells.

### Claim 46 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 19 to 45, wherein said compound comprising fluorine-19 (19F) is a dual-mode agent and is capable of being detected by more than one imaging modality.

### Claim 47 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 19 to 46, wherein said compound comprising fluorine-19 (19F) is a dual-mode agent and is capable of being detected by two or more imaging modalities.

### Claim 48

An in vivo imaging method, comprising
a) ex vivo labeling cells with a cellular labelling composition comprising a compound comprising fluorine-19 (19F) under such conditions that said compound comprising fluorine-19 (19F) according to any of the preceding claims is bound to the cells and/or internalized by the cells;
b) administering the labeled cells to a subject;
c) detecting said labeled cells in said subject using an imaging modality, and
d) assaying for the degree of cell accumulation in one or more tissues in said subject.

### Claim 49 (depends on 48)

The method of claim 48, wherein said assaying comprises quantitating the average total intracellular probe mass at sites of accumulation of said labeled cells.

### Claim 50 (depends on 48, 49)

The method of claim 48 or 49, wherein said cells are autologous cells.

### Claim 51 (depends on 48, 49)

The method of claim 48 or 49, wherein said cells are allogeneic cells.

### Claim 52 (depends on 48, 49, 50, 51)

The method of any one of claims 48 to 51, wherein said imaging modality is selected from the group consisting of magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission coherent tomography (SPECT), ultrasonography (US), and computed tomography (CT).

### Claim 53 (depends on 48, 49, 50, 51)

The method of any one of claims 48 to 51, wherein said imaging modality is magnetic resonance imaging (MRI).

### Claim 54 (depends on 48, 49, 50, 51)

The method of any one of claims 48 to 51, wherein said cells are selected from the group consisting of T cells, B cells, macrophages, natural killer (NK) cells, dendritic cells (DCs), stem cells, progenitor cells, and cancer cells.

### Claim 55 (depends on 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 48 to 54, wherein said cells are engineered cells.

### Claim 56 (depends on 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 48 to 55, wherein said compound comprising fluorine-19 (19F) comprises a perfluorinated compound.

### Claim 57 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 48 to 56, wherein said compound comprises a metal-binding moiety capable of binding metal ions.

### Claim 58 (depends on 57)

The method of claim 57, wherein said metal ions are selected from the group consisting of Co3+, VO2+, Cr3+, Mn2+, Mn3+, Mn4+, Fe2+, Fe3+, Ni2+, Cu2+, Ce3+, Pr3+, Nd3+, Sm3+, Eu3+, Gd3+, Tb3+, Dy3+, Ho3+, Er3+, Tm3+, Yb3+, 44Sc3+, 52Mn2+, 61Cu2+, 64Cu2+, Zn2+, 66Ga3+, 68Ga3+, 82Rb, 86Y3+, 89Zr4, 67Ga3+, 99mTc4+, 111In3+, and 177Lu3+.

### Claim 59 (depends on 57)

The method of claim 57, wherein said metal ions are selected from the group consisting of Fe3+, Fe2+, Ga3+, Mn2+, Mn3+, Mn4+, Ni2+, Cu2+, Zn2+, Co3+, and Cr3+.

### Claim 60 (depends on 57)

The method of claim 57, wherein said metal ions are selected from the group consisting of Mn4+, Fe3+, Co3+, and Ga3+.

### Claim 61 (depends on 57)

The method of claim 57, wherein said metal ion is Fe3+.

### Claim 62 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 48 to 61, wherein said compound has a solubility greater than 0.005 mol/L in perfluorocarbons selected from the group consisting of perfluorooctylbromide (PFOB), perfluoro-15-crown-5-ether (PFCE), and perfluoro (polyethylene glycol) (PFPE).

### Claim 63 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 48 to 62, wherein said compound is stable in pH from 1 to 14.

### Claim 64 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 48 to 63, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound changes the chemical shift of the SALTAME core in 19F nuclear magnetic resonance (19F-NMR).

### Claim 65 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 48 to 64, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound reduces the T1 relaxivity of fluorine-19 (19F) in the SALTAME core.

### Claim 66 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 48 to 65, wherein said compound is formulated as a nanoemulsion.

### Claim 67 (depends on 66)

The method of claim 66, wherein said nanoemulsion further comprises a perfluorocarbon.

### Claim 68 (depends on 66)

The method of claim 66, wherein said nanoemulsion further comprises one or more targeting moieties, wherein the targeting moieties are selected from the group consisting of peptides, binding proteins, antibodies, antibody fragment thereof, and aptamers.

### Claim 69 (depends on 66)

A nanoemulsion formulation comprising the compound of claim 66 in an oil-in-water colloidal suspension or emulsion.

### Claim 70

A pharmaceutical and/or diagnostic composition comprising a nanoemulsion formulation comprising a compound comprising fluorine-19 (19F), wherein said compound comprising fluorine-19 (19F) associates with one or more cells and said association is capable of being detected using an imaging modality.

### Claim 71

A pharmaceutical and/or diagnostic composition comprising a compound comprising a salicylidene-tris(aminomethyl)ethane (SALTAME) core as described herein.

### Claim 72

A pharmaceutical and/or diagnostic composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the following compounds:
wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and R1 to R12 are selected from the group consisting of: H, CH3, perfluorohexyl (PFH), perfluorooctyl (PFO), Me, CF3, O—(CF2)n—CF3, (CF2)n—CF3, and O—CF2—(OCF2CF2)n—O—Y, wherein n is 0 to 20, and Y is CF3, CF2—CF3 or CF2—CF2—CF3;
or
wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and Rf is (CF2)j—CF3 or O—(CF2)j—CF3, wherein j is 0 to 20.

### Claim 73

A pharmaceutical and/or diagnostic composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the group consisting of 5a POP (Fe SALTAME), 5a OOP (Fe SALTAME), 5a OOO (Fe SALTAME), 5c (Fe SALTAME), 5d (Fe SALTAME), 5e (Fe SALTAME), 5f (Fe SALTAME), 5g (Fe SALTAME), GA OOP, and GA POP.

### Claim 74

A pharmaceutical and/or diagnostic composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the following compounds:

### Claim 75 (depends on 71, 72, 73, 74)

The pharmaceutical and/or diagnostic composition of any one of claims 71 to 74, wherein said compound comprising fluorine-19 (19F) comprises a perfluorinated compound.

### Claim 76 (depends on 71, 72, 73, 74, 75)

The pharmaceutical and/or diagnostic composition of any one oaf claims 71 to 75, wherein said compound comprising fluorine-19 (19F) comprises a metalated perfluorinated compound.

### Claim 77 (depends on 71, 72, 73, 74, 75, 76)

The pharmaceutical and/or diagnostic composition of any one of claims 71 to 76, wherein said compound comprises a metal-binding moiety capable of binding metal ions.

### Claim 78 (depends on 77)

The pharmaceutical and/or diagnostic composition of claim 77, wherein said metal ions are selected from the group consisting of Co3+, VO2+, Cr3+, Mn2+, Mn3+, Mn4+, Fe2+, Fe3+, Ni2+, Cu2+, Ce3+, Pr3+, Nd3+, Sm3+, Eu3+, Gd3+, Tb3+, Dy3+, Ho3+, Er3+, Tm3+, Yb3+, 44Sc3+, 52Mn2+, 61Cu2+, 64Cu2+, Zn2+, 66Ga3+, 68Ga3+, 82Rb, 86Y3+, 89Zr4+, 67Ga3+, 99mTc4+, 111In3+ and 177Lu3+.

### Claim 79 (depends on 77)

The pharmaceutical and/or diagnostic composition of claim 77, wherein said metal ions are selected from the group consisting of Fe3+, Fe2+, Ga3+, Mn2+, Mn3+, Mn4+, Ni2+, Cu2+, Zn2+, Co3+, and Cr3+.

### Claim 80 (depends on 77)

The pharmaceutical and/or diagnostic composition of claim 77, wherein said metal ions are selected from the group consisting of Mn4+, Fe3+, Co3+, and Ga3+.

### Claim 81 (depends on 77)

The pharmaceutical and/or diagnostic composition of claim 77, wherein said metal ion is Fe3+.

### Claim 82 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The pharmaceutical and/or diagnostic composition of any one of claims 71 to 81, wherein said compound has a solubility greater than 0.005 mol/L in perfluorocarbons selected from the group consisting of perfluorooctylbromide (PFOB), perfluoro-15-crown-5-ether (PFCE), and perfluoro (polyethylene glycol) (PFPE).

### Claim 83 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The pharmaceutical and/or diagnostic composition of any one of claims 71 to 82, wherein said compound is stable in pH from 1 to 14.

### Claim 84 (depends on 71, 8382)

The pharmaceutical and/or diagnostic composition of any one of claims 71 to 8382, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound changes the chemical shift of the SALTAME core in 19F nuclear magnetic resonance (19F-NMR).

### Claim 85 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The pharmaceutical and/or diagnostic composition of any one of claims 71 to 84, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound reduces the T1 relaxivity of fluorine-19 (19F) in the SALTAME core.

### Claim 86 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The pharmaceutical and/or diagnostic composition of any one of claims 71 to 85, wherein said compound is formulated as a nanoemulsion.

### Claim 87 (depends on 86)

The pharmaceutical and/or diagnostic composition of claim 86, wherein said nanoemulsion further comprises a perfluorocarbon.

### Claim 88 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

A pharmaceutical and/or diagnostic composition comprising at least two or more of said compounds of any one of claims 71 to 87.

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

A compound selected from any one of claims 1 to 88.
